

# Morgan Hakki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2976713/publications.pdf>

Version: 2024-02-01

18  
papers

432  
citations

759233

12  
h-index

888059

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

706  
citing authors

#	ARTICLE	IF	CITATIONS
1	Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 70, 723-730.	5.8	73
2	American Society for Transplantation and Cellular Therapy Series: "Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 707-719.	1.2	45
3	Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible <i>Pseudomonas aeruginosa</i> in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019, 68, 2045-2052.	5.8	43
4	Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13687.	1.7	34
5	The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. <i>Journal of Clinical Virology</i> , 2015, 68, 1-5.	3.1	30
6	Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre. <i>Mycoses</i> , 2019, 62, 665-672.	4.0	29
7	Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. <i>Antiviral Research</i> , 2012, 95, 88-92.	4.1	27
8	Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 90-102.	2.3	27
9	Differential Properties of Cytomegalovirus pUL97 Kinase Isoforms Affect Viral Replication and Maribavir Susceptibility. <i>Journal of Virology</i> , 2014, 88, 4776-4785.	3.4	26
10	Ceftolozane-tazobactam therapy for multidrug-resistant <i>Pseudomonas aeruginosa</i> infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients. <i>Infection</i> , 2018, 46, 431-434.	4.7	25
11	Predictive Value of Testing Nasopharyngeal Samples for Respiratory Viruses in the Setting of Lower Respiratory Tract Disease. <i>Journal of Clinical Microbiology</i> , 2014, 52, 4020-4022.	3.9	22
12	Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. <i>Antiviral Research</i> , 2011, 92, 313-318.	4.1	13
13	Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH) <i>TJ ETQq1 1 0.784314 rgBii/Overlo</i>		
14	Toxoplasmosis in non-cardiac solid organ transplant recipients: A case series and review of literature. <i>Transplant Infectious Disease</i> , 2020, 22, e13218.	1.7	10
15	Long-Term Dominance of Carbapenem-Non-Susceptible <i>Pseudomonas aeruginosa</i> ST111 in Hematologic Malignancy Patients and Hematopoietic Cell Transplant Recipients. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	3.9	6
16	Incidence and Outcomes of Bacterial Bloodstream Infections during Acute Graft-versus-Host Disease Involving the Gastrointestinal Tract after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1648-1653.	2.0	5
17	<i>Coccidioides immitis</i> Cervical Lymphadenitis Complicated by Esophageal Fistula. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-4.	0.5	3
18	Emergence of non-susceptibility during persistent <i>Pseudomonas aeruginosa</i> bacteraemia in haematopoietic cell transplant recipients and haematological malignancy patients. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab125.	2.1	3